Lonza

Newer, more complex targeted therapies are entering clinical development at rapid speeds, requiring facilities to increase manufacturing capacity levels in order to keep up with demands and under the strictest levels of containment.

Learn more about the Capsugel® Enprotect™ capsule and our breakthrough enteric manufacturing technology.

Learn more about the Capsugel® Enprotect® capsule and our breakthrough enteric manufacturing technology.

Learn more about the Capsugel® Enprotect® capsule and our breakthrough enteric manufacturing technology.

Learn more about the Capsugel® Enprotect™ capsule An innovative capsule for enteric delivery with no additional coating required for low pH protection.

Learn more about the Capsugel® Enprotect™ capsule and our breakthrough enteric manufacturing technology.

Drug development is a complicated process, with a huge number of processes and activities required to bring a drug successfully to market. How can an integrated CDMO help a small biotech move a project into and through the clinic, and onto the market? In this podcast, Henny Zijlstra, Senior Director, Commercial Development at Lonza, details why is it faster and more efficient to work with a single supplier.

Learn how the right integrated CDMO can help small biotech companies move a project into and through the clinic and onto the market with ease.

Tuesday, June 14th, 2022 at 7:30am PDT | 9:30am CDT | 10:30am EDT Join Lonza and Quench Medical in a joint discussion about process engineering for the respiratory delivery of gemcitabine to treat lung cancer

Wednesday March 2, 2022 at 11am EST | 4pm GMT | 5pm CET Compounds that are poorly soluble in water are still prevalent in the pharmaceutical industry drug development pipeline. Enabling technologies such as lipid-based formulations (LBF) and amorphous solid dispersions (ASDs) can address these bioavailability limitations, enabling the creation of effective drug products.

Wednesday, February 23rd 2022 at 11am EST | 5pm CET | Molecules with solubility challenges continue to dominate drug development pipelines, increasing the demand for formulation technologies that can solve these issues. Join CMC Consultant, Peter Timmins, Lonza’s Sr. Research Fellow, David Lyon, and Quotient Sciences’ CSO, Peter Scholes, as they outline how a variety of data-driven strategies and integrated program designs can simplify development processes and reduce costs. Using expert insight and case studies they will showcase how spray drying can solve solubility challenges, and demonstrate how integrating GMP manufacturing and clinical testing can rapidly accelerate development timelines.

Thursday, July 22, 2021 at 11am EDT| 8am PDT| 4pm BST| 5pm CEST Local delivery of monoclonal antibodies to the lung is enabled by spray drying to manufacture stable, respirable dry powders. An inhaled formulation of bevacizumab was effective in vivo, reducing tumor burden in a rat model of non-small cell lung cancer.

Two Airings! * NA, EMEA, LATAM: Tuesday, May 18, 2021 at 11am EDT |8am PDT| 4pm BST| 5pm CEST and APAC: Tuesday, May 25, 2021 at 4pm JST| 3pm CST| 5pm AEST| 12:30pm IST* Learn more about possible solutions to help overcome the challenges of formulating poorly absorbable APIs with different oral dosage forms. *On Demand Until May 25, 2022*

***Session 1: Thursday, April 22, 2021, 10am EDT, Session 2: Thursday, April 22, 2021, 11am EDT, Session 3: Thursday, April 22, 2021, 1pm EDT*** A drug’s journey from development to manufacturing to patients is paved with roadblocks and potholes; many threats can derail bio/pharmaceutical processes. Potential solutions to such pitfalls have been discussed for years; however, few manufacturers have embraced technology and process advances to proactively ensure drug supply chain continuity.

***Live: Thursday, March 4 , 2021 at 11am EST| 8am PST| 4pm GMT| 5pm CET & Asia Pacific: Thursday, March 11, 2021 at 4pm JST | 3pm CST | 6pm AEST | 12:30pm IST*** Solid-form screening and characterization is a crucial part of drug substance development and pre-formulation. Review the underlying fundamentals of various screening methods and case studies on in-silico screening methods.*** On demand available after final airing until March 11, 2022.***

• Advantages of using an integrated-service provider • Case study: HPAPI monoplant